


**ISET[®] Blood Cytopathology:
Patient information leaflet**



**FIGHT
FOR A BETTER
LIFE**

ISET
by  Rarecells

*The reference technology for
detecting
Circulating Cancer Cells*


For more information, please visit our website:

www.isetbyrarecells.com

You never really see cancer coming, most of us learn we have a tumor during a routine check-up. Once we have been diagnosed, our fight begins. Yes, cancer is a fight and the ISET® technology may help you win this fight.

CANCER AND TUMOR INVASION

When cells start growing without control in an organ of your body, they form a cancer (or tumor). Cancer cells can then spread from this primary tumor into the blood and invade other organs to form metastases. These cells are called Circulating Cancer Cells (CCC). Metastases are very difficult to treat and are the main reason why we lose our fight against cancer. Once the diffusion of CCC has started and the CCC have been diagnosed and counted, which is now possible thanks to the ISET® Blood Cytopathology, the race against time and disease begins. One can benefit from the early discovery of CCC presence, which can be identified in blood years before metastases develop, to start a suitable therapy as fast as possible, in order to considerably increase its effectiveness.



CCC – EXTRAORDINARY POTENTIAL

Since CCC circulate in the blood years before the development of metastases, they provide an extraordinary tool for identifying patients at risk. Early identification allows appropriate treatment in a timely manner, prevention of metastases formation and treatment efficacy follow-up. CCC are so rare and fragile, that their capture and diagnosis have been a challenge for many years. The ISET® technology has overcome this challenge (as reported by 50 independent scientific publications, see www.rarecells.com). It is a breakthrough in oncology that will dramatically improve the lives of patients with cancer.

ISET® BLOOD CYTOPATHOLOGY

ISET® Blood Cytopathology is based on a simple, painless for the patients blood test. Once the blood is drawn, it is processed by a special device to isolate the CCC. The ISET® Technology is so sensitive that it can detect one single CCC in 10 mL of blood, (i.e.: one CCC mixed with several billions of blood cells). **CCC are spread by all types of solid tumors and ISET® Blood Cytopathology can isolate all types of CCC.** It combines the exceptional capability for isolating intact CCC from blood without loss, their staining, their diagnostic identification and their counting by cytopathology, with unequaled to date sensitivity and specificity. The ISET® analysis relies on cytopathology, which is the only diagnostic reference method in oncology to identify tumor cells. Cytopathology has been validated and used to diagnose cancer for over 150 years.



When performed on patients without diagnosed cancer ISET® Blood Cytopathology does not indicate, in case of positive results of the test, the organ of origin of the CCC, and cannot foretell the time laps before identification of the tumor by imaging is possible. A positive result of the test in the absence of a diagnosed cancer indicates the need for monitoring the subject with the usual methods (imaging, blood tests, endoscopy, etc.). The development of a test which will be able to indicate the organ of origin is ongoing.

The ISET® Technology involves the combination of **30 patented parameters**. Rarecells® and ISET® are registered trademarks of Rarecells SAS. Rarecells SAS and Rarecells Diagnostics SAS are *spin-offs* of **the University Paris Descartes, INSERM and Assistance Publique - Hôpitaux de Paris**.

ISET® Blood Cytopathology

The ISET® Blood Cytopathology is based on a simple blood draw and provides important information for patients with all types of solid cancers:

The CCC are early “sentinel” of tumor invasion (allowing early treatment and metastases prevention).

This sensitive and predictive method allows an optimized management of cancer therapy (monitoring of treatment efficacy)



STL

SafeTestsforLife

Help research on early diagnosis of invasive cancers and its clinical validation by donating at:

www.safetestsforlife.org



© Rarecells Diagnostics
www.Rarecells.com